"The Danish drugmaker employs about 400 people in Athlone. Employees at the site were told on Monday that up to 75 jobs could go, according to the Westmeath Independent. The company confirmed that it had announced a global workforce reduction and said its priority during the process was to support staff. "Out of respect for the employees involved, we will not share additional details about individual sites or areas," a spokesperson said."
"Novo Nordisk added that the restructuring was part of a broader transformation intended to "simplify our organisation, improve decision-making speed, and reallocate resources towards the company's growth opportunities in diabetes and obesity." The company said the organisational changes would help it work more efficiently and "focus on what matters most, driving innovation and reaching many more patients." The Athlone facility, which manufactures drug ingredients for the global supply chain, has expanded in recent years as demand for Novo Nordisk's medicines increased."
Novo Nordisk employs about 400 people at its Athlone, Ireland site where up to 75 jobs may be cut as part of a global workforce reduction. The company prioritizes support for affected employees and declined to share site-specific details. The restructuring aims to simplify the organisation, speed decision-making, and reallocate resources toward diabetes and obesity growth opportunities to drive innovation and reach more patients. The Athlone facility manufactures drug ingredients and expanded amid demand for Ozempic and Wegovy. The firm has faced weaker-than-expected US demand, rising competition from Lilly, leadership changes, a hiring freeze, and reported demotions and pay cuts during restructuring.
Read at Irish Independent
Unable to calculate read time
Collection
[
|
...
]